Background

Henoch-Schönlein syndrome is a systemic small-vessel leukocytoclastic vasculitis that usually present with cutaneous, gastrointestinal, articular and renal manifestations. Little is known on liver involvement in this syndrome. This study investigated liver chemistry and creatine kinase in Henoch-Schönlein children.

Case presentation

Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, total bilirubin, prothrombin time and creatine kinase were assessed in 75 consecutive pediatric patients (41 boys and 34 girls aged from 2.9 to 17 years) with new-onset Henoch-Schönlein syndrome. Mildly altered values were found in 7 (9%) patients (5 boys and 2 girls aged from 3.3 to 17 years). In the mentioned cases, all tests returned to normal at a 2–4-week follow-up.

Conclusions

This preliminary study points out that altered and self-remitting liver parameters occur in approximately 10% of children with Henoch-Schönlein syndrome.

Henoch-Schönlein syndrome, also called immunoglobulin A vasculitis, is the most common systemic vasculitis in childhood [1]. It is a small-vessel leukocytoclastic vasculitis that typically presents with cutaneous, gastrointestinal, articular and renal manifestations [1]. Little is known on liver involvement in this syndrome. Limited data suggest that aminotransferases are elevated in approximately 3% of children with new-onset Henoch-Schönlein syndrome and in cases complicated by acalculous cholecystitis or pancreatitis [2, 3]. Exercise, infectious prodromi or drugs with hepatotoxic potential or a pre-existing liver disease, such as non-alcoholic fatty liver disease, might also alter aminotransferases in Henoch-Schönlein syndrome [4, 5]. Herein, we report our prospective single-center experience with liver chemistry and creatine kinase in 75 consecutive pediatric patients affected by this vasculitis syndrome.

In subjects with abnormal enzyme levels, plasma amylase was determined and a hepatobiliary ultrasound performed. Finally, the blood tests were repeated approximately 2–4 weeks later.

The diagnosis of Henoch-Schönlein syndrome was made using the Ankara 2008 - EULAR/PRINTO/PRES criteria [6]. The CAAR grading system for cutaneous, abdominal, articular, and renal involvement was applied to assess the systemic disease activity [7].

From each case, we collected data on ethnicity, pre-existing chronic conditions, possible triggers (defined as acute illness or vaccination [1, 8] preceding the skin lesions by ≤14 days) and repetitive exercise ≤3 days before admission to the emergency department. A careful drug history, including both prescribed and over-the-counter medications, was also taken.

The liver and spleen borders were estimated clinically at the end of inspiration: the liver border was determined by percussion and palpation in the right mid-clavicular line and the diagnosis of hepatomegaly was made when the liver edge projected >2 cm below the margin [9]; the spleen border was determined by palpation in the left anterior axillary line and the diagnosis of splenomegaly was made when the spleen was palpable [10]. Finally, the Murphy sign was considered positive in cases with pain on inspiration while palpating the right upper abdominal quadrant.

A kinetic assay was used for alanine aminotransferase (reference: <50 U/L), aspartate amintransferase (reference: <50 U/L) and amylase (reference: <120 U/L), an ultraviolet spectrophotometry for lactate dehydrogenase (reference: <500 U/L) and creatine kinase (reference: <150 U/L), a kinetic colorimetry for γ-glutamyltransferase (reference: <50 U/L), a diazo colorimetry for total bilirubin (reference: <20 μmol/L) and an automated clotting assay for prothrombin time (reference: 0.90–1.30 INR). An automated dipstick system was used for hematuria and proteinuria.

Enzyme values were graded as normal or mildly (<5 times the upper reference limit), moderately (5–10 times) and markedly (>10 times) altered. Data analysis was approved of by the Ethical Committee of our hospital. Anonymized patient information was used for data analysis. Data are given either as median and interquartile range or as relative frequency. The one-sample Mann–Whitney–Wilcoxon test was used to compare the results with those of the general population. Significance was assumed when P < 0.05.

Between January 2009 and June 2016, we made the diagnosis of new-onset Henoch-Schönlein syndrome in 72 Caucasian and 3 Hispanic patients up to 17 years of age presented to the Pediatric Emergency Unit. History, clinical findings and renal involvement are given in Table 1. A possible trigger, either an infection or a vaccination, was reported by 49 (65%) patients. Forty-one (55%) cases had been managed with paracetamol, a nonsteroidal anti-inflammatory drug, a penicillin or a macrolide.

Table 1

History, clinical findings and renal involvement in 75 pediatric patients aged from 2.9 to 17 years with new-onset Henoch-Schönlein syndrome. Data are given either as relative frequency or as median and interquartile range

Age, years

6.4 [4.8–7.7]

Gender, ♂: ♀

41: 34

Pre-existing chronic condition, N

0

Recent repetitive exercise

5

Triggers

Acute lower respiratory infection, N

15

Acute upper respiratory infection, N

14

Nonspecific febrile illness, N

10

Urinary tract infection, N

6

Acute diarrheal disease, N

3

Vaccination, N

1

Drug management

Paracetamol, N

31

Nonsteroidal anti-inflammatories, N

12

Penicillins, N

15

Macrolides, N

4

Clinical findings

Hepatomegaly, N

2

Splenomegaly, N

1

Hepatosplenomegaly, N

1

Murphy sign, N

0

Cutaneous involvement

Mild, N

47

Moderate, N

25

Severe, N

3

Abdominal involvement

None, N

28

Mild, N

28

Moderate, N

17

Severe, N

2

Articular involvement

None, N

14

Mild, N

46

Moderate, N

12

Severe, N

3

Renal involvement

None, N

45

Mild, N

22

Moderate, N

7

Severe, N

1

The results of liver chemistry and creatine kinase appear in Fig. 1. As compared with the general population, blood values were not abnormally elevated in Henoch-Schönlein patients.

Enzyme levels were normal in 68 and mildly elevated in the remaining 7 patients. None of them presented with hepatomegaly, splenomegaly or Murphy sign. Circulating amylase and hepatobiliary ultrasound were found to be normal in these cases.

An isolated increase in creatine kinase (175 and 189 U/L, respectively) was observed in two boys (7.5 and 9.3 years of age, respectively) with recent history of repetitive exercise. An increase in plasma creatine kinase (265 U/L), associated with elevated alanine aminotransferase (60 U/L), aspartate aminotransferase (186 U/L) and lactate dehydrogenase (523 U/L) was also observed in a 5.4-year-old boy with recent extended physical activity.

This is the first prospective study investigating liver chemistry and creatine kinase in unselected Henoch-Schönlein children. These tests are normal at presentation in about 90% and mildly elevated in 10% of these patients. In the latter cases, liver parameters are transiently altered and self-remit within 4 weeks. Similar observations were recently made in patients affected with acute hemorrhagic edema of young children, the infantile variant of Henoch-Schönlein syndrome [11].

Exercise likely accounts for the altered tests observed in 3 patients with recent history of extended physical activity [4, 5]. On the contrary, we do not have a clear-cut explanation for the transiently altered liver chemistry noted in the remaining 4 cases. We speculate that altered liver tests resulted either from the infectious prodrome or from unreported self-administration of a drug with hepatotoxic potential. Finally, the strategy used to establish cut off values implies that a result out of range is not necessarily pathologic and is found in 2–3% of healthy subjects.

The findings of this study confirm those of a retrospective analysis including apparently unselected Henoch-Schönlein children from the Republic of China [12]. In that report, mildly elevated alanine aminotransferase levels were observed in 9% of the cases. However, creatine kinase levels were not assessed in those children.

Some months after starting the investigation presented in this report, the use of lower laboratory thresholds for alanine aminotranferase (i.e. 25 U/L instead of 50 U/L) was proposed for children affected by a chronic liver disease [13]. This recommendation deserves in our opinion further support.

The main limitations of this preliminary study were its single center design, the rather small sample size and the ethnic homogeneity of the study population.

Acknowledgements

The authors would like to thank Dr. Alec Villa for his assistance in the linguistic revision.

Funding

None.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the last author on reasonable request.

Authors’ contributions

GR, GPM, EFF, MGB conceptualized the study. GR and EAL conducted the study and collected data. GR, MGB and EFF performed statistical analysis and interpreted the results. GPM and EAL gave a significant contribution on their field of expertise. GPM and MGB wrote the first draft of the manuscript. EEF supervised the whole study. All authors critically reviewed the first draft, approved the final manuscript as submitted and take full responsibility for the manuscript.

Ethics approval and consent to participate

The study was approved by the local ethical committee.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.